RxDoctor Payments Data

Mark Whittington, OD

Optometrist · Charleston, WVNPI 1366925620

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,593 of the $8,029 with a category attached, or 82.1%. 19 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 24.3% of the total. Among optometrist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,029in general payments, 2019–2025

Across 244 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Bausch & Lomb Americas Inc.$2K
  • Coopervision Inc.$896
  • Alcon$733
  • Sun Pharmaceutical Industries Inc.$710
  • Johnson & Johnson Vision Care, Inc.$593
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$1,43618%
  • Food & beverage$6,59382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,029 in reported general payments places this provider in the 95th percentile of 210 optometrist providers in West Virginia.

See all optometrist providers in West Virginia

Medicare billing

Part B allowed, 2024
$79,753
Medicare patients
502
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$30,017
LumiganBimatoprost22$8,266
Doxycycline Hyclate18$1,402
Latanoprost122$1,400
Tobramycin-DexamethasoneTobramycin/Dexamethasone33$1,295
Prednisolone Acetate28$976
Brimonidine Tartrate27$276
Timolol Maleate28$197
Dorzolamide Hcl11$169
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$290$38,28346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 optometrist providers in West Virginia.

Other optometrist in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →